“…A number of detailed studies by different groups showed that Ro15-4513 prevented the increased exploration and locomotion at very low EtOH doses (0.25, 0.5 and 0.75 g/kg in rats) (June & Lewis, 1994), the anxiolytic effects at low doses (1 g/kg in rats) (Suzdak et al, 1986a;Glowa et al, 1988;Becker & Hale, 1991) the sedative, motor impairing, as well as amnestic effects at moderate EtOH doses (2 g/kg rats or mice) (Suzdak et al, 1986a;Bonetti et al, 1988;Nabeshima et al, 1988;Dar, 1995), as well as the anticonvulsant (seizure protective) effects of EtOH (2 g/kg) against bicuculline and picrotoxin-induced convulsions (Kulkarni & Ticku, 1989). In addition, the observation that Ro15-4513 reduces EtOH self-administration (June et al, 1991;Rassnick et al, 1993;Petry, 1995) suggests that the rewarding effects of EtOH might be mediated by EtOH/Ro15-4513-sensitive GABA A R. However, Ro15-4513 does not prevent all EtOH effects: at higher EtOH doses (≥2 g/kg in rats), Ro15-4513 significantly reduces, but does not prevent the anesthetic ("sleep"-inducing) effects of EtOH (Marrosu et al, 1989), and Ro15-4513 does not prevent the hypothermic effects of EtOH (Hoffman et al, 1987;Syapin et al, 1987), consistent with the notion that part of the hypothermic (and analgesic) EtOH actions are mediated by other targets, possibly GIRK K + channels (Blednov et al, 2003;Costa et al, 2005).…”